of all breast cancers, with a higher proportion occurring in younger women and women of African ancestry 1 . The etiology 2 and clinical behavior 3 of ER-negative tumors are different from those of tumors expressing ER (ER positive), including differences in genetic predisposition 4 . To identify susceptibility loci specific to ER-negative disease, we combined in a metaanalysis 3 genome-wide association studies of 4,193 ERnegative breast cancer cases and 35,194 controls with a series of 40 follow-up studies (6,514 cases and 41,455 controls), genotyped using a custom Illumina array, iCOGS, developed by the Collaborative Oncological Gene-environment Study (COGS). SNPs at four loci, 1q32.1 (MDM4, P = 2.1 × 10 −12 and LGR6, P = 1.4 × 10 −8 ), 2p24.1 (P = 4.6 × 10 −8 ) and 16q12.2 (FTO, P = 4.0 × 10 −8 ), were associated with ER-negative but not ER-positive breast cancer (P > 0.05). These findings provide further evidence for distinct etiological pathways associated with invasive ER-positive and ER-negative breast cancers.
ER-negative cases and 41,455 controls of European ancestry from 40 BCAC studies forming part of the COGS Project (Online Methods and Supplementary Table 1 ). Samples were genotyped using the iCOGS custom Illumina Infinium array that included a total of 211,155 SNPs selected in collaboration with other cancer consortia (Online Methods). We performed a fixed-effects meta-analysis of odds ratio (OR) estimates from the GWAS and follow-up studies (quantilequantile plot shown in Supplementary Fig. 1 ) and identified four loci newly associated with ER-negative disease at P < 5 × 10 −8 ( Fig. 1 and Table 1 ; cluster plots shown in Supplementary Fig. 2 ).
Two independently associated loci were located on chromosome 1q32.1 and were tagged by two uncorrelated (r 2 < 0.001) markers (from reference sequence NCBI Build 36): rs4245739 (P = 2.1 × 10 −12 , OR = 1.14, 95% confidence interval (CI) = 1.10-1.18) and rs6678914 (P = 1.4 × 10 −8 , OR = 1.10, 95% CI = 1.06-1.13). Conditional analyses of the two SNPs in BCAC follow-up data showed comparable estimates, indicating that these are two distinct signals (Supplementary Table 2 ). The other two loci were located at 2p24.1 (rs12710696, P = 4.6 × 10 −8 , OR = 1.10, 95% CI = 1.06-1.13) and 16q12.2 (rs11075995, P = 4.0 × 10 −8 , OR = 1.11, 95% CI = 1.07-1.15). For each region, there was little evidence for heterogeneity of effect by study (Table 1 and Supplementary Fig. 3a-d) , and genotype-specific risks for rs4245739, rs6678914 and rs12710696 were consistent with a log-additive model. For rs11075995, departure from a log-additive model was significant (P = 0.039), and genotype-specific estimates suggested a recessive effect (Supplementary Table 3 ).
The strength of the association for each SNP differed significantly by ER status, and none of the SNPs showed significant associations with ER-positive disease in the analysis of 25,227 ER-positive cases and 41,455 controls of European ancestry in BCAC (Supplementary  Tables 4 and 5) . Notably, we observed no significant differences in ORs for ER-negative tumors with and without the triple-negative phenotype (defined as ER-negative, progesterone receptor (PR)-negative and HER2-negative) for rs6678914 (1q32.1, LGR6), rs12710696 (2p24.1) and rs11075995 (16q12.2). However, rs4245739 (1q32.1, MDM4) seemed to be specific to triple-negative tumors (caseonly heterogeneity P value (P het ) by triple-negative status = 0.005; Supplementary Table 5) .
None of the four SNPs showed significant (P < 0.05) associations in studies of Asian ancestry in BCAC, and only the 16q12.2 (FTO) variant was associated at P = 0.05 in combined analyses of studies of AfricanAmerican ancestry in BCAC and the African-American Breast Cancer Consortium 5 (AABC; Supplementary Table 6 ). However, estimates for Asian and African-American populations were not significantly different from those in Europeans (P > 0.05), and larger studies in these populations are needed to determine whether risk associations exist. None of the markers were significantly associated with increasing age at the onset of ER-negative disease in the BCAC follow-up data (P trend ≥ 0.314), although there were some differences in age-specific estimates (Supplementary Table 7) . Furthermore, OR estimates were not significantly different for women with and without a family history of any breast cancer in at least one first-degree relative, and risk alleles were not over-represented in cases with a positive family history (Supplementary Table 8) .
rs4245739 (1q32.1) is located in the 3′ region of the MDM4 oncogene. MDM4 is a repressor of TP53 and TP73 transcription and is important for cell cycle regulation and apoptosis. rs4245739 resides in a linkage disequilibrium (LD) block of approximately 230 kb (Supplementary Fig. 4a ) that also contains the tRNA Lys transcript and the genes PIK3C2B and LRRN2 (Supplementary Fig. 5a ). MDM4, tRNA Lys and PIK3C2B but not LRRN2 are expressed in normal breast epithelium, breast cancer cell lines and breast tumors [9] [10] [11] . There are no nonsynonymous SNPs correlated with rs4245739 in the 1000 Genomes Project populations of European ancestry (r 2 > 0.10); however, correlated SNPs are located in the promoter region of PIK3C2B (rs3014606, r 2 = 0.94 and rs2926534, r 2 = 0.94) and in the tRNA Lys transcript (rs11240753, r 2 = 0.78 and rs4951389, r 2 = 0.78). Variants in the MDM4 locus correlated with rs4245739 have also been associated with breast cancer in BRCA1 mutation carriers who have predominantly ER-negative tumors 12 . Thus, this region seems to be specifically associated with ER-negative disease and not with overall breast cancer risk, as suggested by a previous, smaller candidate gene study 13 . To our knowledge, no studies before the COGS collaboration have evaluated rs4245739 in relation to the risk of ER-negative disease.
rs6678914 on chromosome 1q32.1 is located in intron 1 of the LGR6 gene (Supplementary Fig. 4b ).
LGR6 and several other genes in this region, including UBE2T and PTPN7, are expressed in breast tumors 9 . A correlated SNP (rs12032424, r 2 = 0.96) is located in a putative enhancer region in the same intron of LGR6 in normal breast epithelial cells, although not in the triple-negative breast cancer cell line MDA-MB-231 (Supplementary Fig. 5b ). The rs6678914 SNP is not correlated with nonsynonymous SNPs in LGR6 (r 2 > 0.10 in 1000 Genomes Project populations of European ancestry).
The SNP rs12710696 on chromosome 2p24.1 is located in an intergenic region, more than 200 kb from the nearest gene (OSR1) (Supplementary Fig. 4c ). It is possible that the allele marked by rs12710696 could influence a set of active enhancers, as the region contains multiple overlapping chromatin marks in normal breast epithelial cells and the MDA-MB-231 triple-negative breast cancer cell line ( Supplementary Fig. 5c ).
The signal found on chromosome 16q12.2 is located in the fat massand obesity-associated gene FTO (Supplementary Fig. 4d ). This signal is tagged by rs11075995, located in a ~40-kb LD block in intron 1 of FTO, within an enhancer region that appears to be active in both normal and triple-negative breast cancer cells (Supplementary Fig. 5d ). rs11075995 is located ~40 kb distal to a region in intron 1 that contains multiple SNPs associated with obesity in the Genetic Investigation of ANthropometric Traits (GIANT) Consortium 14, 15 , as well as a SNP associated with overall breast cancer risk (rs17817449) 8 . rs11075995 is not correlated with any of the previously reported SNPs associated with obesity at genome-wide significant levels in GIANT or with rs17817449 (P = 3.7 × 10 −60 , based on 123,864 subjects in GIANT; ref. 15) . However, rs11075995 is associated with body mass index (BMI), both in GIANT (P = 1.51 × 10 −6 , based on 121,427 subjects) and our control population (P = 2.8 × 10 −5 , based on 20,952 controls in iCOGS; data not shown). Analyses adjusting and stratifying by BMI on the basis of 3,071 ER-negative cases and 20,130 controls from 19 studies genotyped on the iCOGS array indicated that the association between rs11075995 and ER-negative disease is not explained or modified by our measure of BMI (BMI-adjusted OR = 1.16, 95% CI = 1.09-1.24, P = 1.1 × 10 −5 ; P interaction = 0.912; data not shown). Furthermore, conditional analyses indicated that the ER-negative disease-specific signal (rs11075995) is independent of rs17817449 (Supplementary Table 2 ). This finding adds to the increasing evidence of distinct signals at the same locus for different subtypes of cancers occurring at the same site, including, for example, 5p15.33 (TERT-CLPTM1L) 16 and 14q24.1 l e t t e r s npg l e t t e r s (RAD51B, also known as RAD51L1) 8 in breast cancer and 5p15.33 (TERT-CLPTM1L) 16 and HNF1B 17 in ovarian cancer. Detailed fine mapping of known and newly identified breast cancer-associated regions will be required to determine whether additional subtypespecific signals exist in these regions.
In an attempt to investigate the likely genes responsible in the observed risk associations, we examined associations between SNPs with available genotype (rs4245739, rs12710696 and rs6678914) and RNA expression in data from 382 primary breast tumors, including 81 ER-negative samples in The Cancer Genome Atlas (TCGA) database. None of the associations were significant after Bonferroni adjustment for multiple comparisons, whether considering only the immediately neighboring genes or all genes within a 1-Mb window of the lead SNP (data not shown). Results are shown for the SNPs showing the strongest association in four loci reaching association P < 5 × 10 −8 in meta-analyses of GWAS and follow-up data. RAF, risk allele frequency; freq., frequency.
a NCBI Build 36. b Imputed (I) and typed (T) SNPs: rs6678914 was typed in one BPC3 study (WGHS), three C-BCAC studies (ABCFS, SASBCAC, UK2) and all TNBCC studies and imputed in all other GWAS studies. c Result of Q test for heterogeneity of estimated ORs.
npg l e t t e r s
To provide a comprehensive analysis of common genetic loci for ERnegative breast cancer, we also evaluated associations between 67 known loci for overall breast cancer risk (26 previously reported and 41 newly identified 8 ) and ER-negative disease. On the basis of our meta-analysis of 10,707 ER-negative cases and 76,649 controls, 7 regions influenced risk of ER-negative disease at P < 5 × 10 −8 : 1p36.22 (PEX14), 5p15 (TERT-CLPTM1L), 2 independent loci at 6q25.1 (ESR1), 12p11.22 (PTHLH), 16q12.1 (TOX3) and 19p13.1 (BABAM1) (Supplementary Table 9 ). Only seven loci identified so far, the four reported here and the three previously reported located at 5p15 (ref. 5), 19p13.1 (ref. 6 ) and 20q11 (ref. 7) , are specific to ER-negative disease.
In summary, our analyses provide further evidence for distinct etiological pathways for invasive ER-positive and ER-negative breast cancers. Fine mapping and functional studies of the susceptibility loci for ER-negative disease should provide important insights into the biological mechanisms of ER-negative breast cancer, potentially leading to the identification of new targets for therapy and prevention of this aggressive form of breast cancer. 
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Accession codes.
Reference sequences for the human genome of the regions containing the following genes are available at NCBI under the indicated accessions: LRRN2, NC_000001.10; UBE2T, NC_000001.10; PTPN7, NC_000001.10; PEX14, NC_000001.10;
LGR6, NC_000001.10; MDM4, NC_000001.10; TP73, NC_ 000001.10; PIK3C2B, NC_000001.10; OSR1, NC_000002.11; TERT, NC_000005.9; CLPTM1L, NC_000005.9; ESR1, NC_000006.11; PTHLH, NC_000012.11; RAD51B, NC_000014.8; FTO, NC_ 000016.9; TOX3, NC_000016.9; HNF1B, NC_000017.10; BRCA1, NC_000017.10; TP53, NC_000017.10; MERIT40, NC_000019.9.
Note: Supplementary information is available in the online version of the paper.
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